UNITED STATES PATENT AND TRADEMARKOFFICE
`
`CERTIFICATE OF CORRECTION
`
`PATENT NO.
`APPLICATION NO.
`
`: 8,536,122 B2
`: 13/412283
`
`DATED
`INVENTOR(S)
`
`: September 17, 2013
`: Jesper Lauetal.
`
`Page 1 of 2
`
`It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shownbelow:
`
`In the Claims
`
`Please replace claim 1, column 123, line 41 with the following:
`
`“Xaa30 is Ala, Glu, or Arg;”
`
`Please replace claim 12, column 125,line 42 to column 132,line 15 with the following:
`
`Ho
`m—-H GEGTFITSDVSSY LEGQAANAE FIAWLYAGR G——o
`OLOH
`AG
`HOAAAAAHyogoA
`
`H
`
`o
`
`o
`
`o
`
`m—H G EGTFTSDVSSYLEGGAANSE FIAWLVAGA G—eon
`GY
`one
`Wytrenetoto
`
`°o
`
`a
`
`6c
`
`Signed and Sealed this
`Fourteenth Day of April, 2015
`
`Wirebstlhe Fo Lea
`
`Michelle K. Lee
`
`Director ofthe United States Patent and Trademark Office
`
`MPI EXHIBIT 1003 PAGE1
`
`MPI EXHIBIT 1003 PAGE 1
`
`

`

`CERTIFICATE OF CORRECTION(continued)
`U.S. Pat. No. 8,536,122 B2
`
`Page 2 of 2
`
`(continued)
`
`m—-H GEGTFISOVSSY LecaaaHLe riawivac A. G——s0a:
`Oy 0H
`»
`L
`HyHlgotyood
`
`a
`
`metSeater rsovssy LEGGAANSE FIAWLVAGR Gascon
`’
`4
`Wrtigenhryodyonoit
`
`6
`
`Qo
`
`o
`
`H,C GH,
`
`H
`mH G EGTFTSDVSSY LEGQAANSE FIAWLY RGR Gor
`
`Worrytnotynoeoyie
`
`oda
`
`oO
`
`H
`
`0
`
`mH G EGTFTSDVSSY LEGOAANSE FIAWLVAGR Gaon
`
`oNyeenordh
`
`o 60
`
`oO
`
`nyeoN
`
`H,¢0°
`
`“cH,
`
`H
`
`i
`
`corrtsovesvieconatfderi nwiv aon on
`7
`4
`G
`WAALigrandyomOnegyNH
`
`Qa o'9
`
`Q
`
`A
`
`o
`
`™m—-H GEGTFTSOVSSY LecoaatlLe FIAWLYAGA Go
`4
`cmmeeaapgotueod,~Oony
`
`Ho
`
`and
`
`wotLe or rrsovesyvitaonehDe pin wivnc poe
`ne”
`“cH,
`Y
`
`ORSOOeeOe.
`
`MPI EXHIBIT 1003 PAGE 2
`
`MPI EXHIBIT 1003 PAGE 2
`
`

`

`Docket No.: 7140.214-US
`(PATENT)
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`In re Letters Patent of:
`Jesper Lauet al.
`
`Patent No.: 8,536,122
`
`Issued: September 17, 2013
`
`For: Acylated GLP-1 Compounds
`
`REQUEST FOR CERTIFICATE OF CORRECTION
`PURSUANTTO 37 C.E.R.§1.322
`
`Attention: Certificate of Correction Branch
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Dear Madam:
`
`Upon reviewing the above-identified patent, Patentee noted typographical errors which
`
`should be corrected.
`
`In the Claims:
`
`At column 123, claim number1, line number 41, please replace ““Xaa33 is Ala, Glu or
`
`Arg;” with “Xaazo is Ala, Glu or Arg;”
`
`7140.214-US - Request for Certificate of Correction -- PTO Error -- no fee required (87 CFR 1.322).doc
`
`MPI EXHIBIT 1003 PAGE 3
`
`MPI EXHIBIT 1003 PAGE 3
`
`

`

`Patent No.: 8,536,122
`
`Docket No.: 7140.214-US
`
`At column 125, line 42 to column 132, line 15, claim number12, please replace with the
`
`following:
`
`H O
`““—-H G EGTFTSDVSSY LEGQAAN AE FIAWLVRGRG
`0° OH
`4
`A
`HORAAAAAAAAT,NgongVoNH
`
`oO
`
`H
`
`O
`
`Oo
`
` ‘COOH
`
`H O
`NH—H G EGTFTSDVSSYLEGQAAN JE FIAWLVAGR G
`
` ‘COOH
`
`AL
`QOH
`WAARAAStenonroOoOM
`
`°
`
`H
`
`°
`
`0
`
`H O
`“s—-H G EGTFTSDVSSY LEGQAA—NLEFIAWLVRGRG
`0° OH
`UL
`
`Oo
`
`H
`
` ‘COOH
`
`O
`
`A
`
`O
`
`H
`
`O
`
`H O
`H O
`F-EGTFTSDVSSYLEGQAANJEFIAWLVRGR G
`we-HN
`H,C CH,
`i
`
`AL
`9
`H
`H
`HOONNNNNgNgOnEyOnYNoO
`
`O00 O
`
` ‘COOH
`
`“HG EGTFTSDVSSY LEGQAANLE FIAWLVRGR G
`
`H
`
` ‘GOOH
`
`°
`H
`H
`Oo
`HOD
`SNOAOm0
`9 00
`O
`H
`O
`
`MPI EXHIBIT 1003 PAGE 4
`
`MPI EXHIBIT 1003 PAGE 4
`
`

`

`Patent No.: 8,536,122
`
`Docket No.: 7140.214-US
`
`H 9
`NHy—H G EGTFTSDVSSYLEGQAANJE FIAWLVRGR G
`
` ‘COOH
`
`9tAigtonetynoon
`
`Oo 00
`
`3
`
`4H
`ff
`Hf
`wortPe stetsovssyrecoaatNee | AW LV RG R G—eco0H
`H.C”
`“CH,
`i
`
`HOYNNNNNsootyoop
`
`?
`
`H
`
`oOo
`
`0
`H
`“w—-H G EGTFTSDVSSY LEGQAANSLE FIAWLVRGRG
`
` ‘COOH
`
`Sos phontyoo
`
`and
`
`&
`H
`tk
`H
`HN EGTtTFTsSovssyteacaaanJe riawtvaGgae
`H.C”
`“CH,
`z
`
`AL
`OH
`O.
`OH
`AL
`N
`Th x.
`N ue NM? yoo
`oO
`°
`
`°
`
`
`
`The errors were not in the application as filed by applicant; accordingly no fee is
`
`required.
`
`Transmitted herewith is a proposed Certificate of Correction effecting such amendment.
`
`Patentee respectfully solicits the granting of the requested Certificate of Correction.
`
`Applicant believes no fee is due with this request. However,if a fee is due, please
`
`charge our Deposit Account No. 14-1447, under Order No. 7140.214-US from which the
`
`undersignedis authorized to draw.
`
`MPI EXHIBIT 1003 PAGE 5
`
`MPI EXHIBIT 1003 PAGE 5
`
`

`

`Patent No.: 8,536,122
`
`Docket No.: 7140.214-US
`
`Dated: January 19, 2015
`
`Respectfully submitted,
`Electronic signature:
`/Richard W. Bork, Reg. No. 36,459/
`Richard W. Bork
`Registration No.: 36,459
`NOVO NORDISK INC
`800 Scudders Mill Road
`Plainsboro, New Jersey 08536
`(609) 987-5800
`Attorney For Applicant
`
`MPI EXHIBIT 1003 PAGE 6
`
`MPI EXHIBIT 1003 PAGE 6
`
`

`

`PTO/SB/44 (09-07)
`Approvedfor use through 08/31/2013. OMB 0651-0033
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`(Also Form PTO-1050)
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`CERTIFICATE OF CORRECTION
`
`PATENT NO.
`
`:
`
`8,536,122
`
`
`
`APPLICATION NO.—: 13/412,283
`
`ISSUE DATE
`
`INVENTOR(S)
`
`:
`
`:
`
`September 17, 2013
`
`Jesper Lau etal.
`
`“Xaazq is Ala, Glu, or Arg;”
`
`It is certified that an error appears or errors appearin the above-identified patent and that said
`Letters Patent is hereby corrected as shown below:
`
`Please replace claim 1, column 123,line 41 with the following:
`
`MAILING ADDRESS OF SENDER (Please do not use customer number below):
`Richard W. Bork
`NOVO NORDISK INC
`800 Scudders Mill Road
`Plainsboro, New Jersey 08536
`7140.214-US - Certificate of Correction (PTO SB-44).doc
`
`1
`
`MPI EXHIBIT 1003 PAGE 7
`
`MPI EXHIBIT 1003 PAGE 7
`
`

`

`PTO/SB/44 (09-07)
`Approvedfor use through 08/31/2013. OMB 0651-0033
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`(Also Form PTO-1050)
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`CERTIFICATE OF CORRECTION
`
`PATENT NO.
`
`:
`
`8,536,122
`
`
`
`APPLICATION NO.—: 13/412,283
`
`ISSUE DATE
`
`INVENTOR(S)
`
`:
`
`:
`
`September 17, 2013
`
`Jesper Lau etal.
`
`It is certified that an error appears or errors appearin the above-identified patent and that said
`Letters Patent is hereby corrected as shown below:
`
`Please replace claim 12, column 125,line 42 to column 132, line 15 with the following:
`
`H O
`“—-H G EGTFTSDVSSY_LEGQAAN J+A € FIAWLVRGRG
`o
`H
`A
`HOAAAAAAAATtgorsgoei
`
`oO
`
`Os OH
`
`H
`
`O
`
`O
`
`cOoH
`
`Oo
`
`YQ
`H
`9
`HyAAAAAAStnotoOtOYMH
`
`Oo
`
`OH
`
`Oy,
`
`H
`
`Oo
`
`H O
`m—-H GEGTFTSDVSSYLEGQAAN JE FIAWLVAGR G
`
`COOH
`
`MAILING ADDRESS OF SENDER (Please do not use customer number below):
`Richard W. Bork
`NOVO NORDISK INC
`800 Scudders Mill Road
`Plainsboro, New Jersey 08536
`7140.214-US - Certificate of Correction (PTO SB-44).doc
`
`2
`
`MPI EXHIBIT 1003 PAGE 8
`
`MPI EXHIBIT 1003 PAGE 8
`
`

`

`PTO/SB/44 (09-07)
`Approvedfor use through 08/31/2013. OMB 0651-0033
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`CERTIFICATE OF CORRECTION
`
`PATENT NO.
`
`:
`
`8,536,122
`
`
`
`APPLICATION NO.—: 13/412,283
`
`September 17, 2013
`
`Jesper Lau etal.
`
`ISSUE DATE
`
`INVENTOR(S)
`
`:
`
`:
`
`(continued)
`
`H O
`“s—-H G EGTFTSDVSSY LEGQAA—NLEFIAWLVRGRG
`
`AL
`9Oxs-0H
`HAAAAAAAALAtptoso
`
`H
`
`H
`
`Oo
`
`0
`
`H
`
`Oo
`
`(Also Form PTO-1050)
`
`Oo
`
`whteat FTSDVSSY LecanmJe riawLvRa R
`HWartiloodyonopli
`
`H,C CH,
`
`Oo 6'O
`
`°
`
`G
`
`H O
`NH—=—H G EGTFTSDVSSYLEGQAANAE FIAWLVRGR G
`
`°
`
`HOSAAAygtnotyvoy
`
`H
`
`Oo 00
`
`MAILING ADDRESS OF SENDER (Please do not use customer number below):
`Richard W. Bork
`NOVO NORDISK INC
`800 Scudders Mill Road
`Plainsboro, New Jersey 08536
`7140.214-US - Certificate of Correction (PTO SB-44).doc
`
`3
`
`MPI EXHIBIT 100
`
`3 PAGE 9
`
`MPI EXHIBIT 1003 PAGE 9
`
`

`

`PTO/SB/44 (09-07)
`Approvedfor use through 08/31/2013. OMB 0651-0033
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`(Also Form PTO-1050)
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`CERTIFICATE OF CORRECTION
`
`PATENT NO.
`
`:
`
`8,536,122
`
`
`
`APPLICATION NO.—: 13/412,283
`
`ISSUE DATE
`
`INVENTOR(S)
`
`:
`
`:
`
`September 17, 2013
`
`Jesper Lau etal.
`
`(continued)
`
`H O
`Nwie—H G EGTFTSDVSSYLEGQAANLE FIAWLVRGR G
`
`9
`
`tAhgthnonotyoy
`
`H
`
`Oo 00
`
`oO
`
`H
`
`phonohynovo
`
`oO
`
`H
`
`H.C’
`3
`
`“CH
`
`3
`
`wortestetsovsesyrecoaatHeri awit va ce cow
`
`HONNNNNsootyoo
`
`H
`
`oOo
`
`oO
`
`0
`
`H
`
`HoHG EGTETSBYSSY LEGOAMIYTEFIANLVRGR
`Soon
`
`OOK
`
`MAILING ADDRESS OF SENDER (Please do not use customer number below):
`Richard W. Bork
`NOVO NORDISK INC
`800 Scudders Mill Road
`Plainsboro, New Jersey 08536
`7140.214-US - Certificate of Correction (PTO SB-44).doc
`
`4
`
`MPI EXHIBIT 1003 PAGE 10
`
`MPI EXHIBIT 1003 PAGE 10
`
`

`

`PTO/SB/44 (09-07)
`Approvedfor use through 08/31/2013. OMB 0651-0033
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`(Also Form PTO-1050)
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`CERTIFICATE OF CORRECTION
`
`PATENT NO.
`
`:
`
`8,536,122
`
`
`
`APPLICATION NO.—: 13/412,283
`
`ISSUE DATE
`
`INVENTOR(S)
`
`:
`
`:
`
`September 17, 2013
`
`Jesper Lau etal.
`
`(continued)
`
`and
`
`9
`9
`H
`H
`mt,Je GTFTfSODVS SY LEGQAA aNte FIA WLYV RGR G
`H,C”
`“CH,
`
`4
`
`NH
`
`oN0
`
`Cpeeeee
`
`H
`NUN ~vohk ON,
`ng
`N 1 oO
`N
`
`MAILING ADDRESS OF SENDER (Please do not use customer number below):
`Richard W. Bork
`NOVO NORDISK INC
`800 Scudders Mill Road
`Plainsboro, New Jersey 08536
`7140.214-US - Certificate of Correction (PTO SB-44).doc
`
`5
`
`MPI EXHIBIT 1003 PAGE11
`
`MPI EXHIBIT 1003 PAGE 11
`
`

`

`
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and TrademarkOffice
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`www .uspto.g:
`Alexandria, Virginia 22313-1450
`
`APPLICATION NO.
`
`13/412,283
`
`ISSUE DATE
`
`09/17/2013
`
`PATENT NO.
`
`ATTORNEY DOCKETNO.
`
`CONFIRMATION NO.
`
`8536122
`
`7140.214-US
`
`9438
`
`23650
`
`7590
`
`08/28/2013
`
`NOVO NORDISK INC.
`INTELLECTUAL PROPERTY DEPARTMENT
`800 Scudders Mill Road
`Plainsboro, NJ 08536
`
`The projected patent numberandissue date are specified above.
`
`ISSUE NOTIFICATION
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include
`an indication of the adjustmenton the front page.
`
`If a Continued Prosecution Application (CPA) wasfiled in the above-identified application, the filing date that
`determines Patent Term Adjustmentis the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEBsite (http://pair-uspto. gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the
`Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee
`payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management
`(ODM)at (571)-272-4200.
`
`APPLICANT(s) (Please see PAIR WEBsite http://pair.uspto.gov for additional applicants):
`
`Jesper Lau, Farum, DENMARK;
`Florencio Zaragoza Dérwald, Smorum, DENMARK;
`Paw Bloch, Taastrup, DENMARK;
`Thomas Kruse Hansen, Herley, DENMARK;
`
`The United States represents the largest, most dynamic marketplace in the world andis an unparalleled location
`for business investment, innovation, and commercialization of new technologies. The USA offers tremendous
`resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation
`works to encourage andfacilitate business investment. To learn more about why the USAis the best country in
`the world to develop technology, manufacture products, and grow your business, visit SelectUSA. gov.
`
`IR103 (Rev. 10/09)
`
`MPI EXHIBIT 1003 PAGE 12
`
`MPI EXHIBIT 1003 PAGE 12
`
`

`

`OK TO ENTER:
`
`/M.M.C.G/
`
`Attorney Docket No.: 7140.214-US
`
`PATENT
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`In re Patent Application of:
`Jesper Lauet al.
`
`Application No.: 13/412,283
`
`Confirmation No.: 9438
`
`Filed: March 5, 2012
`
`Art Unit: 1658
`
`For: Acylated GLP-1 Compounds
`
`Examiner: M. M. Cordero Garcia
`
`AMENDMENT AFTER ALLOWANCE UNDER37 C.F.R. 1.312
`
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Madam:
`
`Prior to issuance of the patent, applicant respectfully requests entry on this amendment
`
`under 37 C.F.R. 1.312 for the above-captioned patent application.
`
`AMENDMENTS TO THE CLAIMS are reflected in the Listing of Claims which
`
`begins on page 2 of this paper.
`
`REMARKSbegin on page 10 of this paper.
`
`MPI EXHIBIT 1003 PAGE 13
`
`MPI EXHIBIT 1003 PAGE 13
`
`

`

`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Attorney Docket No.: 7140.214-US
`Page 2 of 10
`
`AMENDMENTSTO THE CLAIMS:
`The following Listing of Claimsreplacesall prior versions, andlistings, of claims.
`
`LISTING OF CLAIMS
`
`32.
`
`(Currently Amended) A compound of formula II (SEQ ID No. 3):
`
`Xaa,-Xaa,-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Xaa_,_-Ser-Xaa,.-Xaa,9-Xaa.-Glu-Xaa,.-
`9
`Xaa,,-Ala-Xaay—NJ—.xaa,-Phe-lle-Xaa,,-Trp-Leu-Xaa,,-Xaaz,-Xaa35-X8azg-XAA37-KXAAge
`
`H
`
`UNH
`
`1O
`
`
`
`wherein
`
`Xaazis L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, B-hydroxy-histidine,
`
`homohistidine, N°-acetyl-histidine, a-fluoromethyl-histidine, a-methyl-histidine, 3-pyridylalanine, 2-
`
`pyridylalanine, or 4-pyridylalanine;
`
`Xaag is Ata; Gly, Val, Leu, lle, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl)
`
`carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-
`
`aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid;
`
`Xaaze is Val or Leu;
`
`Xaaie is Ser, Lys, or Arg;
`
`Xaaig is Tyr or Gln;
`
`Xaav is Leu or Met;
`
`Xaaz2 is Gly, Glu, or Aib;
`
`Xaaz3 is Gln, Glu, Lys, or Arg;
`
`Xaagzs is Ala or Val;
`
`Xaa7 is Glu or Leu;
`
`MPI EXHIBIT 1003 PAGE 14
`
`MPI EXHIBIT 1003 PAGE 14
`
`

`

`Attorney Docket No.: 7140.214-US
`Page 3 of 10
`
`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Xaago is Ala, Glu, or Arg;
`
`Xaaq3 is Val or Lys;
`
`Xaaaa4 is Lys, Glu, Asn, or Arg;
`
`Xaags is Gly or Aib;
`
`Xaage is Arg, Gly, Lys, or is absent;
`
`Xaazz is Gly, Ala, Glu, Pro, Lys, or is absent;
`
`Xaage is Lys, Ser, amide, or is absent; and
`
`where U is a spacer selected from
`
`9Oy0H
`
`0
`
`tyinooNyoo ~tyhHnotoe 4
`
`QO OH
`
`4
`
`4
`
`where n is 12, 13, 14, 15, 16, 17, or 18,
`
`lis 12, 13, 14, 15, 16, 17, or 18,
`
`m is 0, 1, 2, 3, 4, 5, or 6,
`
`sis 0, 1, 2, or 3,
`
`pis 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, 22, or 23; and
`
`MPI EXHIBIT 1003 PAGE 15
`
`MPI EXHIBIT 1003 PAGE 15
`
`

`

`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Attorney Docket No.: 7140.214-US
`Page 4 of 10
`
`whereBis an acidic group selected from
`
`H
`
`HON Ho
`O
`O
`
`and
`
`;
`
`33.
`
`(Currently Amended) A GLP-1 analog according to claim 32, wherein
`
`Xaaz is His or desamino-histidine;
`
`Xaasgis Ata; Gly, Val, Leu, lle, Lys or Aib;
`
`Xaaig is Val;
`
`Xaaig is Ser;
`
`Xaaig is Tyr;
`
`Xaaqzo is Leu;
`
`Xaaq is Gly, Glu or Aib;
`
`Xaaz3 is Gln or Glu;
`
`Xaagzsis Ala;
`
`Xaao7 is Glu;
`
`Xaago is Ala or Glu;
`
`Xaagz is Val;
`
`Xaazq is Lys or Arg;
`
`Xaags is Gly or Aib;
`
`Xaaze is Arg or Lys
`
`Xaazz is Gly, amide or is absent; and
`
`MPI EXHIBIT 1003 PAGE 16
`
`MPI EXHIBIT 1003 PAGE 16
`
`

`

`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Xaazg is absent.
`
`Attorney Docket No.: 7140.214-US
`Page 5 of 10
`
`34.
`
`(Previously Presented) A GLP-1 analog according to claim 33, wherein
`
`Xaaz is His
`
`Xaazgis Gly, or Aib;
`
`Xaaig is Val;
`
`Xaaig is Ser;
`
`Xaaig is Tyr;
`
`Xaaqo is Leu;
`
`Xaaz2 is Glu or Aib;
`
`Xaazz3 is Gln;
`
`Xaagzsis Ala;
`
`Xaaz7is Glu;
`
`Xaazpois Ala;
`
`Xaagz is Val;
`
`Xaagq is Lys or Arg;
`
`Xaags is Gly or Aib;
`
`Xaage is Arg
`
`Xaasz7 is Gly and
`
`Xaazg is absent.
`
`MPI EXHIBIT 1003 PAGE 17
`
`MPI EXHIBIT 1003 PAGE 17
`
`

`

`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Attorney Docket No.: 7140.214-US
`Page 6 of 10
`
`(Previously Presented) A GLP-1 analog according to claim 32, wherein said GLP-1 analog
`35.
`comprises Aib® or Gly’ in position 8 of the GLP-1(7-37) sequence.
`
`(Previously Presented) A GLP-1 analog according to claim 35, wherein said GLP-1 analog
`36.
`comprises Aib®.
`
`37.
`
`(Previously Presented) A GLP-1 analog according to claim 32, wherein said GLP-1 analog
`
`comprises no morethan six amino acid residues which have been exchanged, added or deleted as
`
`compared to GLP-1(7-37) (SEQ ID No. 1).
`
`38.
`
`(Previously Presented) A GLP-1 analog according to claim 32, wherein said GLP-1 analog
`
`comprises no more than 3 amino acid residues which have been exchanged, added or deleted as
`
`compared to GLP-1(7-37) (SEQ ID No. 1).
`
`39.
`
`(Previously Presented) A GLP-1 analog according to claim 32, wherein said GLP-1 analog
`
`comprises only one lysine residue.
`
`40.
`
`(Previously Presented) A GLP-1 analog according to claim 32, which is
`
`Aib®,Arg*-GLP-1 (7-37) or
`
`Aib®”?Arg™-GLP-1(7-37).
`
`(Previously Presented) A compound according to claim 32, wherein U is a spacer selected
`
`41.
`
`from
`
`MPI EXHIBIT 1003 PAGE 18
`
`MPI EXHIBIT 1003 PAGE 18
`
`

`

`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Attorney Docket No.: 7140.214-US
`Page 7 of 10
`
`QOH
`
`0
`
`QOH,
`
`and
`
`.
`
`42.
`
`(Previously Presented) A compound according to claim 41, wherein B is
`
`HON
`Oo
`
`43.
`
`(Currently Amended) A compound according to claim 32 selected from the following:
`
`H
`
`NHQ> HAEGTFTSDVSSYLEGQAA—N_2—EF | AWLVRG R G-coon
`
`H O
`m—H G EGTFTSDVSSYLEGQAANDE ciAWLVRGRG
`oO 0H
`A
`HORAAAAAANegrngOL
`
`O
`
`H
`
`O
`
`O
`
` ‘COOH
`
`H O
`nH G EGTFTSDVSSYLEGQAAN JE FIAWLVRGR G
`
` ‘COOH
`
`A
`H
`9
`HyAARARKtetoooOoOH
`
`Oo
`
`Oxy,
`
`H
`
`OH
`
`Oo
`
`0
`
`H O
`Ny—H G EGTFTSDVSSYLEGQAA—NULE FIAWLVRGRG
`
` COOH
`
`O
`
`09 OH
`
`4
`
`H
`
`O
`
`9
`
`H
`
`A
`
`O
`
`MPI EXHIBIT 1003 PAGE 19
`
`MPI EXHIBIT 1003 PAGE 19
`
`

`

`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Attorney Docket No.: 7140.214-US
`Page 8 of 10
`
`H ©
`H 9
`m-HNAEGTFTSDVSSYLEGQAANJEFIAWLVRGR G
`H,C CH,
`i
`
` ‘COOH
`
`O
`H
`H
`oO
`HOMENOAyOyNH
`Oo 00
`oO
`H
`oO
`
`H O
`““—-H G EGTFTSDVSSYLEGQAANJLE FIAWLVRGR G
`
` ‘COOH
`
`0
`
`H
`
`H
`
`0
`
`oO 860
`
`Au
`6
`HOSSNNNNNNNgNegSOO9NH
`
`°
`
`H 9
`“—H G EGTFTSDVSSYLEGQAAN LE FIAWLVRGR G
`
` COOH
`
`4
`9
`H
`H
`HOAAAAtoyoo
`
`0
`
`oO
`
`O
`
`O
`
`H Oo
`“—H A EGTFTSDVSSYLEGQAAN LE FIAWLVRGR G
`
`
`
`>,1h0
`HOONNANANgNNNONON
`
`0
`
`oO
`
`O
`
`O
`
`9
`
`9°
`
`H
`
`wtDee GTFTSODVSSYLEGQA awJL—e Fl AW LVR G R G—cccH
`H.C’
`‘CH,
`i
`
`oO
`H
`H
`Oo
`HOTSNNNOAyNO9eH
`Oo 0'O
`O
`H
`oO
`
`oO
`H
`Niy—H G EGTFTSDVSSYLEGQAANJE FIAWLVRGR G
`0
`AU
`0
`HONARR H
`C
`NApNOAOLNyNH
`O
`H
`O
`COOH
`
`O
`
` ‘COOH
`
`and
`
`MPI EXHIBIT 1003 PAGE 20
`
`MPI EXHIBIT 1003 PAGE 20
`
`

`

`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Attorney Docket No.: 7140.214-US
`Page 9 of 10
`
`9
`9
`H
`H
`HN EGTFETSoOVSsyYLEGaAANJE FiAWLEVRGERG
`H.C”
`“CH,
`:
`
`AL
`OH
`0.
`OH
`TO A
`N "NNO yoo
`3
`°o
`
`°
`
`
`
`44.
`
`(Previously Presented) A pharmaceutical composition comprising a compound according to
`
`claim 32, and a pharmaceutically acceptable excipient.
`
`45.
`
`(Previously Presented) A pharmaceutical composition comprising a compound according to
`
`claim 43, and a pharmaceutically acceptable excipient.
`
`46.
`
`(Previously Presented) A methodfor treating hyperglycemia and/or type 2 diabetesin a
`
`subject, said method comprising administering to a subject in need of such treatment an effective
`
`amount of a GLP-1 analog according to claim 32.
`
`47.
`
`(Previously Presented) A methodfor treating hyperglycemia and/or type 2 diabetesin a
`
`subject, said method comprising administering to a subject in need of such treatment an effective
`
`amount of a GLP-1 analog according to claim 43.
`
`MPI EXHIBIT 1003 PAGE 21
`
`MPI EXHIBIT 1003 PAGE 21
`
`

`

`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Attorney Docket No.: 7140.214-US
`Page 10 of 10
`
`Summary of Claim Amendments and Pending Claims
`
`Byentry of the present amendment, claims 32, 33 and 43 have been amended to remove Ala
`
`as an amino acid option at position 8 of the claimed compounds. Accordingly, claims 32-47 are
`
`pendingandat issue, and claim 32 is an independent claim. No new matter has been added by these
`
`amendments.
`
`Conclusion
`
`Applicant believes no fee is due with this response. However, if a fee is due, please charge
`
`our Deposit Account No. 14-1447, under Order No. 7140.214-US from which the undersigned is
`
`authorized to draw.
`
`The undersigned invites the Examiner to contact him by telephoneif there are any questions
`
`concerning this amendmentor application.
`
`Dated: August 6, 2013
`
`Respectfully submitted,
`
`/Richard W. Bork, Reg. No. 36,459/
`Richard W. Bork, Reg. No. 36,459
`Novo Nordisk Inc
`Customer Number: 23650
`(609) 987-5800
`
`Please use the following customer numberforall correspondence regardingthis application.
`*23650*
`PATENT TRADEMARK OFFICE
`
`MPI EXHIBIT 1003 PAGE 22
`
`MPI EXHIBIT 1003 PAGE 22
`
`

`

`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`
`
`
` FILING DATE
`
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`
`
`
`CONFIRMATIONNO.
`
`
`13/412,283
`
`03/05/2012
`
`Jesper Lau
`
`7140.214-US
`
`9438
`
`08/12/2013
`
`7590
`23650
`NOVO NORDISK INC.
`INTELLECTUAL PROPERTY DEPARTMENT
`800 Scudders Mill Road
`Plainsboro, NJ 08536
`
`CORDERO GARCIA, MARCELA M
`
`1658
`
`
`
`
`NOTIFICATION DATE
`
`DELIVERY MODE
`
`08/12/2013
`
`ELECTRONIC
`
`Please find below and/or attached an Office communication concerning this application or proceeding.
`
`The time period for reply, if any, is set in the attached communication.
`
`Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the
`following e-mail address(es):
`nnipatent @ novonordisk.com
`KSHL @novonordisk.com
`KISW @novonordisk.com
`
`PTOL-90A (Rev. 04/07)
`
`MPI EXHIBIT 1003 PAGE 23
`
`MPI EXHIBIT 1003 PAGE 23
`
`

`

`
`Application No.
`Applicant(s)
`
`
`
`Responseto Rule 312 Communication
`
`13/412,283
`
`Examiner
`
`GARCIA
`
`MARCELA M. CORDERO
`
`LAU ET AL.
`
`Art Unit
`
`1658
`
`-- The MAILING DATEof this communication appears on the cover sheet with the correspondence address —
`
`1. KJ The amendmentfiled on 06 August 2013 under 37 CFR 1.312 has been considered, and has been:
`
`a) KX] entered.
`
`b) (1) entered as directed to matters of form not affecting the scopeofthe invention.
`
`c)(] disapproved because the amendmentwasfiled after the paymentofthe issue fee.
`
`Any amendment filed after the date the issue fee is paid must be accompaniedby a petition under 37 CFR 1.313(c)(1)
`
`and the required fee to withdraw the application from issue.
`
`d)(] disapproved. See explanation below.
`
`e)( entered in part. See explanation below.
`
`/KARLHEINZ R SKOWRONEK/
`Supervisory Patent Examiner, Art Unit 1658
`
`Primary Examiner, Art Unit 1658 U.S. Patent and Trademark Office
`
`/MARCELA M GCORDERO GARCIA/
`
`PTOL-271 (Rev. 04-01)
`
`Reponseto Rule 312 Communication
`
`Part of Paper No. 20130807
`
`MPI EXHIBIT 1003 PAGE 24
`
`MPI EXHIBIT 1003 PAGE 24
`
`

`

`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Attorney Docket No.: 7140.214-US
`Page 2 of 10
`
`AMENDMENTSTO THE CLAIMS:
`The following Listing of Claimsreplacesall prior versions, andlistings, of claims.
`
`LISTING OF CLAIMS
`
`32.
`
`(Currently Amended) A compound of formula II (SEQ ID No. 3):
`
`Xaa,-Xaa,-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Xaa_,_-Ser-Xaa,.-Xaa,9-Xaa.-Glu-Xaa,.-
`9
`Xaa,,-Ala-Xaay—NJ—.xaa,-Phe-lle-Xaa,,-Trp-Leu-Xaa,,-Xaaz,-Xaa35-X8azg-XAA37-KXAAge
`
`H
`
`UNH
`
`1O
`
`
`
`wherein
`
`Xaazis L-histidine, D-histidine, desamino-histidine, 2-amino-histidine, B-hydroxy-histidine,
`
`homohistidine, N°-acetyl-histidine, a-fluoromethyl-histidine, a-methyl-histidine, 3-pyridylalanine, 2-
`
`pyridylalanine, or 4-pyridylalanine;
`
`Xaag is Ata; Gly, Val, Leu, lle, Lys, Aib, (1-aminocyclopropyl) carboxylic acid, (1-aminocyclobutyl)
`
`carboxylic acid, (1-aminocyclopentyl) carboxylic acid, (1-aminocyclohexyl) carboxylic acid, (1-
`
`aminocycloheptyl) carboxylic acid, or (1-aminocyclooctyl) carboxylic acid;
`
`Xaaze is Val or Leu;
`
`Xaaie is Ser, Lys, or Arg;
`
`Xaaig is Tyr or Gln;
`
`Xaav is Leu or Met;
`
`Xaaz2 is Gly, Glu, or Aib;
`
`Xaaz3 is Gln, Glu, Lys, or Arg;
`
`Xaagzs is Ala or Val;
`
`Xaa7 is Glu or Leu;
`
`MPI EXHIBIT 1003 PAGE 25
`
`MPI EXHIBIT 1003 PAGE 25
`
`

`

`Attorney Docket No.: 7140.214-US
`Page 3 of 10
`
`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Xaago is Ala, Glu, or Arg;
`
`Xaaq3 is Val or Lys;
`
`Xaaaa4 is Lys, Glu, Asn, or Arg;
`
`Xaags is Gly or Aib;
`
`Xaage is Arg, Gly, Lys, or is absent;
`
`Xaazz is Gly, Ala, Glu, Pro, Lys, or is absent;
`
`Xaage is Lys, Ser, amide, or is absent; and
`
`where U is a spacer selected from
`
`9Oy0H
`
`0
`
`tyinooNyoo ~tyhHnotoe 4
`
`QO OH
`
`4
`
`4
`
`where n is 12, 13, 14, 15, 16, 17, or 18,
`
`lis 12, 13, 14, 15, 16, 17, or 18,
`
`m is 0, 1, 2, 3, 4, 5, or 6,
`
`sis 0, 1, 2, or 3,
`
`pis 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 21, 22, or 23; and
`
`MPI EXHIBIT 1003 PAGE 26
`
`MPI EXHIBIT 1003 PAGE 26
`
`

`

`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Attorney Docket No.: 7140.214-US
`Page 4 of 10
`
`whereBis an acidic group selected from
`
`H
`
`HON Ho
`O
`O
`
`and
`
`;
`
`33.
`
`(Currently Amended) A GLP-1 analog according to claim 32, wherein
`
`Xaaz is His or desamino-histidine;
`
`Xaasgis Ata; Gly, Val, Leu, lle, Lys or Aib;
`
`Xaaig is Val;
`
`Xaaig is Ser;
`
`Xaaig is Tyr;
`
`Xaaqzo is Leu;
`
`Xaaq is Gly, Glu or Aib;
`
`Xaaz3 is Gln or Glu;
`
`Xaagzsis Ala;
`
`Xaao7 is Glu;
`
`Xaago is Ala or Glu;
`
`Xaagz is Val;
`
`Xaazq is Lys or Arg;
`
`Xaags is Gly or Aib;
`
`Xaaze is Arg or Lys
`
`Xaazz is Gly, amide or is absent; and
`
`MPI EXHIBIT 1003 PAGE 27
`
`MPI EXHIBIT 1003 PAGE 27
`
`

`

`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Xaazg is absent.
`
`Attorney Docket No.: 7140.214-US
`Page 5 of 10
`
`34.
`
`(Previously Presented) A GLP-1 analog according to claim 33, wherein
`
`Xaaz is His
`
`Xaazgis Gly, or Aib;
`
`Xaaig is Val;
`
`Xaaig is Ser;
`
`Xaaig is Tyr;
`
`Xaaqo is Leu;
`
`Xaaz2 is Glu or Aib;
`
`Xaazz3 is Gln;
`
`Xaagzsis Ala;
`
`Xaaz7is Glu;
`
`Xaazpois Ala;
`
`Xaagz is Val;
`
`Xaagq is Lys or Arg;
`
`Xaags is Gly or Aib;
`
`Xaage is Arg
`
`Xaasz7 is Gly and
`
`Xaazg is absent.
`
`MPI EXHIBIT 1003 PAGE 28
`
`MPI EXHIBIT 1003 PAGE 28
`
`

`

`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Attorney Docket No.: 7140.214-US
`Page 6 of 10
`
`(Previously Presented) A GLP-1 analog according to claim 32, wherein said GLP-1 analog
`35.
`comprises Aib® or Gly’ in position 8 of the GLP-1(7-37) sequence.
`
`(Previously Presented) A GLP-1 analog according to claim 35, wherein said GLP-1 analog
`36.
`comprises Aib®.
`
`37.
`
`(Previously Presented) A GLP-1 analog according to claim 32, wherein said GLP-1 analog
`
`comprises no morethan six amino acid residues which have been exchanged, added or deleted as
`
`compared to GLP-1(7-37) (SEQ ID No. 1).
`
`38.
`
`(Previously Presented) A GLP-1 analog according to claim 32, wherein said GLP-1 analog
`
`comprises no more than 3 amino acid residues which have been exchanged, added or deleted as
`
`compared to GLP-1(7-37) (SEQ ID No. 1).
`
`39.
`
`(Previously Presented) A GLP-1 analog according to claim 32, wherein said GLP-1 analog
`
`comprises only one lysine residue.
`
`40.
`
`(Previously Presented) A GLP-1 analog according to claim 32, which is
`
`Aib®,Arg*-GLP-1 (7-37) or
`
`Aib®”?Arg™-GLP-1(7-37).
`
`(Previously Presented) A compound according to claim 32, wherein U is a spacer selected
`
`41.
`
`from
`
`MPI EXHIBIT 1003 PAGE 29
`
`MPI EXHIBIT 1003 PAGE 29
`
`

`

`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Attorney Docket No.: 7140.214-US
`Page 7 of 10
`
`QOH
`
`0
`
`QOH,
`
`and
`
`.
`
`42.
`
`(Previously Presented) A compound according to claim 41, wherein B is
`
`HON
`Oo
`
`43.
`
`(Currently Amended) A compound according to claim 32 selected from the following:
`
`H
`
`NHQ> HAEGTFTSDVSSYLEGQAA—N_2—EF | AWLVRG R G-coon
`
`H O
`m—H G EGTFTSDVSSYLEGQAANDE ciAWLVRGRG
`oO 0H
`A
`HORAAAAAANegrngOL
`
`O
`
`H
`
`O
`
`O
`
` ‘COOH
`
`H O
`nH G EGTFTSDVSSYLEGQAAN JE FIAWLVRGR G
`
` ‘COOH
`
`A
`H
`9
`HyAARARKtetoooOoOH
`
`Oo
`
`Oxy,
`
`H
`
`OH
`
`Oo
`
`0
`
`H O
`Ny—H G EGTFTSDVSSYLEGQAA—NULE FIAWLVRGRG
`
` COOH
`
`O
`
`09 OH
`
`4
`
`H
`
`O
`
`9
`
`H
`
`A
`
`O
`
`MPI EXHIBIT 1003 PAGE 30
`
`MPI EXHIBIT 1003 PAGE 30
`
`

`

`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Attorney Docket No.: 7140.214-US
`Page 8 of 10
`
`H ©
`H 9
`m-HNAEGTFTSDVSSYLEGQAANJEFIAWLVRGR G
`H,C CH,
`i
`
` ‘COOH
`
`O
`H
`H
`oO
`HOMENOAyOyNH
`Oo 00
`oO
`H
`oO
`
`H O
`““—-H G EGTFTSDVSSYLEGQAANJLE FIAWLVRGR G
`
` ‘COOH
`
`0
`
`H
`
`H
`
`0
`
`oO 860
`
`Au
`6
`HOSSNNNNNNNgNegSOO9NH
`
`°
`
`H 9
`“—H G EGTFTSDVSSYLEGQAAN LE FIAWLVRGR G
`
` COOH
`
`4
`9
`H
`H
`HOAAAAtoyoo
`
`0
`
`oO
`
`O
`
`O
`
`H Oo
`“—H A EGTFTSDVSSYLEGQAAN LE FIAWLVRGR G
`
`
`
`>,1h0
`HOONNANANgNNNONON
`
`0
`
`oO
`
`O
`
`O
`
`9
`
`9°
`
`H
`
`wtDee GTFTSODVSSYLEGQA awJL—e Fl AW LVR G R G—cccH
`H.C’
`‘CH,
`i
`
`oO
`H
`H
`Oo
`HOTSNNNOAyNO9eH
`Oo 0'O
`O
`H
`oO
`
`oO
`H
`Niy—H G EGTFTSDVSSYLEGQAANJE FIAWLVRGR G
`0
`AU
`0
`HONARR H
`C
`NApNOAOLNyNH
`O
`H
`O
`COOH
`
`O
`
` ‘COOH
`
`and
`
`MPI EXHIBIT 1003 PAGE 31
`
`MPI EXHIBIT 1003 PAGE 31
`
`

`

`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Attorney Docket No.: 7140.214-US
`Page 9 of 10
`
`9
`9
`H
`H
`HN EGTFETSoOVSsyYLEGaAANJE FiAWLEVRGERG
`H.C”
`“CH,
`:
`
`AL
`OH
`0.
`OH
`TO A
`N "NNO yoo
`3
`°o
`
`°
`
`
`
`44.
`
`(Previously Presented) A pharmaceutical composition comprising a compound according to
`
`claim 32, and a pharmaceutically acceptable excipient.
`
`45.
`
`(Previously Presented) A pharmaceutical composition comprising a compound according to
`
`claim 43, and a pharmaceutically acceptable excipient.
`
`46.
`
`(Previously Presented) A methodfor treating hyperglycemia and/or type 2 diabetesin a
`
`subject, said method comprising administering to a subject in need of such treatment an effective
`
`amount of a GLP-1 analog according to claim 32.
`
`47.
`
`(Previously Presented) A methodfor treating hyperglycemia and/or type 2 diabetesin a
`
`subject, said method comprising administering to a subject in need of such treatment an effective
`
`amount of a GLP-1 analog according to claim 43.
`
`MPI EXHIBIT 1003 PAGE 32
`
`MPI EXHIBIT 1003 PAGE 32
`
`

`

`Application No. 13/412,283
`Amendment under 37 C.F.R. 1.312
`
`Attorney Docket No.: 7140.214-US
`Page 10 of 10
`
`Summary of Claim Amendments and Pending Claims
`
`Byentry of the present amendment, claims 32, 33 and 43 have been amended to remove Ala
`
`as an amino acid option at position 8 of the claimed compounds. Accordingly, claims 32-47 are
`
`pendingandat issue, and claim 32 is an independent claim. No new matter has been added by these
`
`amendments.
`
`Conclusion
`
`Applicant believes no fee is due with this response. However, if a fee is due, please charge
`
`our Deposit Account No. 14-1447, under Order No. 7140.214-US from which the undersigned is
`
`authorized to draw.
`
`The undersigned invites the Examiner to contact him by telephoneif there are any questions
`
`concerning this amendmentor application.
`
`Dated: August 6, 2013
`
`Respectfully submitted,
`
`/Richard W. Bork, Reg. No. 36,459/
`Richard W. Bork, Reg. No. 36,459
`Novo Nordisk Inc
`Customer Number: 23650
`(609) 987-5800
`
`Please use the following customer numberforall correspondence regardingthis application.
`*23650*
`PATENT TRADEMARK OFFICE
`
`MPI EXHIBIT 1003 PAGE 33
`
`MPI EXHIBIT 1003 PAGE 33
`
`

`

`
`
`i m
`
`ee
`
`Paymentinformation:
`
`Submitted with Payment
`
`yes
`
`Deposit Account
`
`141447
`
`
`
`TheDirector of the USPTO is hereby authorized to charge indicated fees and credit any overpaymentas follows:
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)
`
`MPI EXHIBIT 1003 PAGE 34
`
`Electronic AcknowledgementReceipt
`
`eine
`
`Title of Invention:
`
`ACYLATED GLP-1 COMPOUNDS
`
`MPI EXHIBIT 1003 PAGE 34
`
`

`

`Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)
`
`Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)
`
`File Listing:
`
`Document
`
`Information:
`
`gs
`
`File Size(Bytes)/
`
`Multi
`
`Pages
`
`Miscellaneous Incoming Letter
`9
`
`7140214USPetitionCorrectinv
`entor.pdf
`
`26d71699845e3cd741 eb55b76d610da266)
`534520
`
`Application Data Sheet
`
`7140214US_SADS.pdf
`
`db3c1cOc2bee7968908eac3172148e51482|
`al7cB
`
`This is not an USPTO supplied ADS fillable form
`
`;
`Amendmentafter Notice of Allowance
`(Rule 312)
`
`7140214US_312_AMEND.pdf
`
`a257377aa7e937152e47047f7b65ff79c708
`9cel
`
`155480
`
`Information:
`
`Fee Worksheet (SB06)
`
`fee-info.pdf
`
`e8ecc141d507e4938643b0d223c427d3708
`Qeacb
`
`the application.
`
`NewInternational Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary componentsfor
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/RO/105)will be issued in due course, subject to prescriptions concerning
`national security, and the date shownon this AcknowledgementReceiptwill establish the international filing date of
`
`This AcknowledgementReceipt evidences receipt on the noted date by the USPTOofthe indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidenceof receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary componentsfora filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shownonthis
`AcknowledgementReceiptwill establish thefiling date of the application.
`
`Natio